Target：KCTD7

Gene Name：KCTD7

Protein Name：KCTD7

Human Gene Id：154881

Human Swiss Prot No：Q96MP8

Mouse Gene Id：212919

Mouse Swiss Prot No：Q8BJK1

Immunogen：Synthesized peptide derived from human KCTD7. at AA range: 181-230

Specificity：This antibody detects endogenous levels of KCTD7

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500-2000;IHC 1:50-300; ELISA 2000-20000

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：BTB/POZ domain-containing protein KCTD7

Observed Band(KD)：33kD

Background： This gene encodes a member of the potassium channel tetramerization domain-containing protein family. Family members are identified on a structural basis and contain an amino-terminal domain similar to the T1 domain present in the voltage-gated potassium channel. Mutations in this gene have been associated with progressive myoclonic epilepsy-3. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Jan 2011],

Function：disease:Defects in KCTD7 are the cause of progressive myoclonic epilepsy type 3 (EPM3) [MIM:611726]. EPM3 is an autosomal recessive, severe, progressive myoclonic epilepsy with early-onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include mental retardation, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges.,similarity:Contains 1 BTB (POZ) domain.,

Subcellular Location：Cell membrane. Cytoplasm, cytosol.

Expression： Brain,